Terms: = Lymphoma AND NTRK1, ENSG00000198400, 4914, P04629, TRK1, MTC, DKFZp781I14186, p140-TrkA, TRKA, TRK AND Treatment
44 results:
1. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing.
Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y
Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853
[TBL] [Abstract] [Full Text] [Related]
2. ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via
Chuang TP; Lai WY; Gabre JL; Lind DE; Umapathy G; Bokhari AA; Bergman B; Kristenson L; Thorén FB; Le A; Doebele RC; Van den Eynden J; Palmer RH; Hallberg B
Proc Natl Acad Sci U S A; 2023 Feb; 120(8):e2216479120. PubMed ID: 36791109
[TBL] [Abstract] [Full Text] [Related]
3. Crocetin ameliorates non-alcoholic fatty liver disease by modulating mitochondrial dysfunction in L02 cells and zebrafish model.
Xu Z; Lin S; Tong Z; Chen S; Cao Y; Li Q; Jiang Y; Cai W; Tong Y; Zahra BS; Wang P
J Ethnopharmacol; 2022 Mar; 285():114873. PubMed ID: 34848360
[TBL] [Abstract] [Full Text] [Related]
4. Luxeptinib disables NLRP3 inflammasome-mediated IL-1β release and pathways required for secretion of inflammatory cytokines IL-6 and TNFα.
Sonowal H; Zhang H; Rice W; Howell SB
Biochem Pharmacol; 2022 Jan; 195():114861. PubMed ID: 34843717
[TBL] [Abstract] [Full Text] [Related]
5. Entrectinib: A Review in Ntrk+ Solid Tumours and ROS1+ NSCLC.
Frampton JE
Drugs; 2021 Apr; 81(6):697-708. PubMed ID: 33871816
[TBL] [Abstract] [Full Text] [Related]
6. The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements.
Delgado J; Pean E; Melchiorri D; Migali C; Josephson F; Enzmann H; Pignatti F
ESMO Open; 2021 Apr; 6(2):100087. PubMed ID: 33735800
[TBL] [Abstract] [Full Text] [Related]
7. Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.
Nakazawa A
Pathol Int; 2021 Apr; 71(4):232-244. PubMed ID: 33657257
[TBL] [Abstract] [Full Text] [Related]
8. Breast metastasis from medullary carcinoma of thyroid: A case report with literature view.
Mukhtar R; Hussain M; Mukhtar MA; Ali SM
J Pak Med Assoc; 2020 Nov; 70(11):2051-2053. PubMed ID: 33341859
[TBL] [Abstract] [Full Text] [Related]
9. Lorlatinib for the treatment of inflammatory myofibroblastic tumour with TPM4-ALK fusion following failure of entrectinib.
Wong HH; Bentley H; Bulusu VR; Anyaegbu G; Watkins J; Horan G; Hatcher H
Anticancer Drugs; 2020 Nov; 31(10):1106-1110. PubMed ID: 32868646
[TBL] [Abstract] [Full Text] [Related]
10. Ntrk and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer.
Leal JL; Peters G; Szaumkessel M; Leong T; Asadi K; Rivalland G; Do H; Senko C; Mitchell PL; Quing CZ; Dobrovic A; Thapa B; John T
Lung Cancer; 2020 Aug; 146():154-159. PubMed ID: 32540558
[TBL] [Abstract] [Full Text] [Related]
11. Tumor-Agnostic treatment for Cancer: When How is Better than Where.
Lavacchi D; Roviello G; D'Angelo A
Clin Drug Investig; 2020 Jun; 40(6):519-527. PubMed ID: 32307639
[TBL] [Abstract] [Full Text] [Related]
12. Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019.
Lau DK; Burge M; Roy A; Chau I; Haller DG; Shapiro JD; Peeters M; Pavlakis N; Karapetis CS; Tebbutt NC; Segelov E; Price TJ
Expert Rev Anticancer Ther; 2020 Apr; 20(4):251-270. PubMed ID: 32186929
[No Abstract] [Full Text] [Related]
13. Larotrectinib in trk fusion-positive pediatric B-cell acute lymphoblastic leukemia.
Schewe DM; Lenk L; Vogiatzi F; Winterberg D; Rademacher AV; Buchmann S; Henry D; Bergmann AK; Cario G; Cox MC
Blood Adv; 2019 Nov; 3(22):3499-3502. PubMed ID: 31725893
[TBL] [Abstract] [Full Text] [Related]
14. Entrectinib: First Global Approval.
Al-Salama ZT; Keam SJ
Drugs; 2019 Sep; 79(13):1477-1483. PubMed ID: 31372957
[TBL] [Abstract] [Full Text] [Related]
15. A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas.
Lin CC; Arkenau HT; Lu S; Sachdev J; de Castro Carpeño J; Mita M; Dziadziuszko R; Su WC; Bobilev D; Hughes L; Chan J; Zhang ZY; Weiss GJ
Br J Cancer; 2019 Jul; 121(2):131-138. PubMed ID: 31217479
[TBL] [Abstract] [Full Text] [Related]
16. Entrectinib and other ALK/trk inhibitors for the treatment of neuroblastoma.
Pacenta HL; Macy ME
Drug Des Devel Ther; 2018; 12():3549-3561. PubMed ID: 30425456
[TBL] [Abstract] [Full Text] [Related]
17. Larotrectinib (LOXO-101).
Berger S; Martens UM; Bochum S
Recent Results Cancer Res; 2018; 211():141-151. PubMed ID: 30069765
[TBL] [Abstract] [Full Text] [Related]
18. Pharmacological inhibition of Receptor Protein Tyrosine Phosphatase β/ζ (PTPRZ1) modulates behavioral responses to ethanol.
Fernández-Calle R; Vicente-Rodríguez M; Pastor M; Gramage E; Di Geronimo B; Zapico JM; Coderch C; Pérez-García C; Lasek AW; de Pascual-Teresa B; Ramos A; Herradón G
Neuropharmacology; 2018 Jul; 137():86-95. PubMed ID: 29753117
[TBL] [Abstract] [Full Text] [Related]
19. Safety and Antitumor Activity of the Multitargeted Pan-trk, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARtrk-1).
Drilon A; Siena S; Ou SI; Patel M; Ahn MJ; Lee J; Bauer TM; Farago AF; Wheler JJ; Liu SV; Doebele R; Giannetta L; Cerea G; Marrapese G; Schirru M; Amatu A; Bencardino K; Palmeri L; Sartore-Bianchi A; Vanzulli A; Cresta S; Damian S; Duca M; Ardini E; Li G; Christiansen J; Kowalski K; Johnson AD; Patel R; Luo D; Chow-Maneval E; Hornby Z; Multani PS; Shaw AT; De Braud FG
Cancer Discov; 2017 Apr; 7(4):400-409. PubMed ID: 28183697
[TBL] [Abstract] [Full Text] [Related]
20. New Targets in Non-Small Cell Lung Cancer.
Park SJ; More S; Murtuza A; Woodward BD; Husain H
Hematol Oncol Clin North Am; 2017 Feb; 31(1):113-129. PubMed ID: 27912827
[TBL] [Abstract] [Full Text] [Related]
[Next]
